Back to Screener

Healthcare

Sonoma Pharmaceuticals, Inc.(SNOA)

Live Price

Offline

$1.15

+0.00% today

1Y Change

-62.24%

Window

Jun 23, 2025 โ†’ Jun 15, 2026

Market Cap
โ€”
Revenue Growth
+12.2%
EPS Growth
+47.6%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 23, 2025 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Sonoma Pharmaceuticals, Inc. (SNOA) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.15 and down 62.2% across the available one-year price window (Jun 23, 2025 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of +12.2%, EPS growth of +47.6%, a dividend yield of 0.0%. What stands out right now is revenue +12.2%, EPS +47.6%, free cash flow +93.0% with operating margin -15.6% and ROIC -28.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines SNOA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+12.2% vs +7.6% peer median

Operating Margin

Below sector median

-15.6% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating story is still moving forward

Revenue is running at +12.2% and EPS at +47.6%, with operating margin around -15.6%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SNOA

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SNOA Max Drawdown

-81.12%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SNOA and SPY.

Calendar-year return history is still loading or unavailable.
Sonoma Pharmaceuticals, Inc. logo

Company Overview

Sonoma Pharmaceuticals, Inc.

NASDAQ Capital Market

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Leadership
Amy Trombly
IPO Date
Jan 25, 2007
Employees
10
Street Address
645 Molly Lane
Mailing
Woodstock, GA, 30189
Region
Woodstock, GA, US
Reporting Currency
USD
Investor Line
800 759 9305
Last Updated
May 4, 2026
CIK: 0001367083ISIN: US83558L3033CUSIP: 83558L303
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
0.1
Price/Book
0.6

Growth

Revenue
+12.2%
EPS
+47.6%
Free Cash Flow
+93.0%

Profitability

Gross Margin
38.2%
Operating Margin
-15.6%
Net Margin
-19.0%
ROE
-85.9%
ROIC
-28.3%

Balance Sheet

Debt/Equity
0.19
Current Ratio
2.88

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.